New cancer drug trial targets advanced tumors with simple injection
NCT ID NCT04891198
Summary
This study is testing whether an immunotherapy drug called ENVAFOLIMAB can help control advanced solid tumors that have stopped responding to standard treatments. About 126 patients with various advanced cancers will receive the drug as a simple injection under the skin every four weeks. Researchers want to see if the drug shrinks tumors and how long the benefit lasts, particularly for patients whose tumors have specific genetic features.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.